Science Links Japan | Clinical Significance of Antibodies to Glutamic Acid Decarboxylase in Diabetic Patients with Secondary Failure of Oral Hypoglycemic Agents.

Clinical Significance of Antibodies to Glutamic Acid Decarboxylase in Diabetic Patients with Secondary Failure of Oral Hypoglycemic Agents.

Accession number;01A0391390

Title;Clinical Significance of Antibodies to Glutamic Acid Decarboxylase in Diabetic Patients with Secondary Failure of Oral Hypoglycemic Agents.

Author; IKEZAWA YOSHIHIRO (Nisseki Nagaokasekijujibyoin Naikatonyobyose) KAMOI KYUJI (Nisseki Nagaokasekijujibyoin Naikatonyobyose) TAKAGI MASATO (Nisseki Nagaokasekijujibyoin Naikatonyobyose) KANEKO KANEZO (Nisseki Nagaokasekijujibyoin Naikatonyobyose) SASAKI HIDEO (Nisseki Nagaokasekijujibyoin Naikatonyobyose)

Journal Title;Journal of the Japan Diabetic Society

Journal Code:Z0279B

ISSN:0021-437X

VOL.44;NO.2;PAGE.141-146(2001)

Figure&Table&Reference;FIG.1, TBL.3, REF.17

Pub. Country;Japan

Language;Japanese

Abstract;The aim of this study was to evaluate the prevalence and clinical significance of antibodies to glutamic acid decarboxylase (anti-GAD) in 103 diabetic patients with secondary failure of sulfonylurea agents (SU-F). The percentage of anti-GAD positive cases among the SU-F patients was 28.2%. The mean interval (8.9years) between the discovery of diabetes and the institution of insulin therapy in the patients with anti-GAD antibody was shorter (p<0.05) than in the patients without anti-GAD antibody (12.1years). The mean body mass index (21.1kg/m2) of the anti-GAD-positive patients was lower (p<0.05) than that of the anti-GAD-negative patients (23.1kg/m2). The mean urinary C-peptide excretion of the anti-GAD-positive patients was lower than that of the anti-GAD-negative patients (29.MU.g/day vs. 65.MU.g/day, p<0.05), and the insulin dose then required was higher (0.67U/kg/day vs.0.37U/kg/day, p<0.05). In conclusion, nearly 30% of DM-SF patients were anti-GAD-antibody-positive, suggesting that an autoimmune mechanism may play an important role in the pathogenesis in some diabetic patients with secondary failure of sulfonylurea agents. Patients who appear to have type 2 diabetes should be examined carefully by determining whether they are positive for autoantibody to GAD. (author abst.)

Related Articles;